Codexis Inc

Codexis gears up for Q1 earnings, boosting RNAi production with ECO Synthesis while expanding biocatalyst reach—read how this could reshape pharma manufacturing.

Codexis, a biotech leader in biocatalyst tech, fuels greener pharma & fine‑chemical production—yet faces profitability hurdles amid market shifts.

Codexis, Inc., a biotechnology company specializing in biocatalysts, continues to play a key role in the pharmaceutical and fine chemicals industries, despite facing financial challenges, through its commitment to sustainable manufacturing practices.

Codexis, a biotechnology firm, continues to innovate in the life sciences tools and services industry, despite recent financial challenges, with its long-term prospects driven by its commitment to biocatalysis technology and sustainable manufacturin…

Codexis, Inc. is a pioneering biotechnology company specializing in biocatalysis, offering innovative solutions for the pharmaceutical and fine chemicals industries through its proprietary technology, despite facing financial challenges in the volat…

Codexis, Inc. is a biotechnology company that specializes in developing biocatalysts for the pharmaceutical and fine chemicals industries, with a market capitalization of approximately $254.55 million.

Codexis Inc, a biotechnology company, reported a 91% surge in revenue to $15.3 million in Q2 2025, exceeding expectations and solidifying its position in the life sciences tools and services sector.

Codexis Inc, a biotech company, is on shaky financial ground and faces questions about its ability to deliver on its innovative promises, sparking concerns about a potential breakdown rather than a breakthrough.

Codexis, Inc. stands at a critical juncture, with its financial instability and intense competition in the biotechnology sector threatening its future prospects.

Codexis, Inc. remains a leader in biocatalysis, poised for long-term success despite current challenges, as the company’s focus on sustainable manufacturing solutions positions it for growth in the evolving biotechnology sector.